Profile data is unavailable for this security.
About the company
InventisBio Co Ltd is a China-based company mainly engaged in the research and development of innovative drugs. The Company's main product is still in clinical development. The Company's core products mainly focus on major disease areas such as oncology and metabolic diseases. The Company's products include D-0120, D-0502, D-1553, BPI-D0316 and others.
- Revenue in CNY (TTM)194.13m
- Net income in CNY-249.28m
- Incorporated2013
- Employees221.00
- LocationInventisBio Co LtdNo.4 Building, Lane 67, Libing RoadSHANGHAI 201203ChinaCHN
- Phone+86 2 150778527
- Fax+86 2 150778527
- Websitehttp://www.inventisbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jiangsu Jibeier Pharmaceutical Co Ltd | 889.82m | 233.59m | 4.73bn | 1.45k | 20.09 | 2.41 | -- | 5.31 | 1.24 | 1.24 | 4.74 | 10.37 | 0.426 | 3.13 | 5.33 | 615,794.80 | 11.17 | 9.77 | 12.06 | 10.66 | 87.87 | 88.44 | 26.22 | 23.29 | 6.76 | -- | 0.005 | 30.68 | 31.49 | 12.16 | 41.65 | 17.79 | 112.78 | -- |
| Beijing Kawin Technol Sha-hld Co Ltd | 1.43bn | 117.53m | 4.83bn | 584.00 | 39.98 | 2.66 | -- | 3.37 | 0.7061 | 0.7061 | 8.61 | 10.60 | 0.6264 | 1.66 | 4.42 | 2,451,945.00 | 6.11 | 5.31 | 7.69 | 6.76 | 82.35 | 86.02 | 9.76 | 8.10 | 3.25 | -- | 0.0809 | 43.82 | 21.73 | 14.87 | 39.71 | 21.04 | 25.01 | -- |
| HitGen Inc | 409.13m | 64.05m | 4.90bn | 452.00 | 76.31 | 3.55 | -- | 11.97 | 0.1601 | 0.1601 | 1.02 | 3.44 | 0.241 | 6.70 | 4.84 | 905,165.50 | 3.77 | 4.63 | 4.02 | 5.10 | 51.46 | 58.89 | 15.66 | 20.66 | 14.48 | 360.77 | 0.142 | 19.14 | 12.64 | 19.69 | 61.16 | -1.96 | -6.12 | -- |
| InventisBio Co Ltd | 194.13m | -249.28m | 4.92bn | 221.00 | -- | 2.54 | -- | 25.34 | -0.4289 | -0.4289 | 0.3348 | 3.35 | 0.0898 | -- | 1.96 | 878,429.50 | -11.53 | -- | -12.26 | -- | 97.85 | -- | -128.41 | -- | -- | -- | 0.0054 | -- | -- | -- | 41.26 | -- | -- | -- |
| Shanghai Hile Bio-Technology Co Ltd | 239.79m | 44.92m | 5.00bn | 295.00 | 113.60 | 4.00 | -- | 20.85 | 0.0669 | 0.0669 | 0.3664 | 1.90 | 0.154 | 1.06 | 2.40 | 812,857.50 | 2.06 | 1.73 | 2.56 | 2.47 | 45.19 | 50.44 | 13.37 | 10.37 | 1.16 | -- | 0.0562 | 23.89 | -19.76 | -1.11 | -48.30 | 24.17 | -41.32 | 23.47 |
| Shanghai Haixin Group Co Ltd | 1.11bn | 171.70m | 5.05bn | 760.00 | 39.52 | 1.72 | -- | 4.55 | 0.1422 | 0.1422 | 0.9185 | 3.27 | 0.2246 | 7.19 | 9.32 | 1,458,849.00 | 4.05 | 2.68 | 4.57 | 3.06 | 46.37 | 44.55 | 18.02 | 11.17 | 2.83 | -- | 0.0089 | 36.10 | -17.88 | 1.48 | 1.20 | 4.19 | -10.27 | 13.18 |
| Hunan Fangsheng Pharmaceutical Co Ltd | 1.63bn | 193.23m | 5.25bn | 1.69k | 26.97 | 3.42 | -- | 3.22 | 0.4428 | 0.4428 | 3.72 | 3.49 | 0.5227 | 1.48 | 6.56 | 966,866.90 | 5.93 | 5.39 | 9.72 | 9.37 | 67.75 | 66.91 | 11.34 | 8.95 | 0.5527 | 16.41 | 0.3447 | 46.47 | -9.12 | 9.15 | -34.64 | 20.68 | 23.91 | 4.75 |
Data as of May 27 2024. Currency figures normalised to InventisBio Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
66.40%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 13.27m | 12.63% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 31 Dec 2023 | 11.45m | 10.90% |
| Bank of China Investment Management Co., Ltd.as of 31 Dec 2023 | 9.24m | 8.80% |
| Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 7.98m | 7.59% |
| First Seafront Fund Management Co., Ltd.as of 31 Dec 2023 | 6.96m | 6.63% |
| Zhonghai Fund Management Co., Ltd.as of 31 Dec 2023 | 5.60m | 5.33% |
| Maxwealth Fund Management Co., Ltd.as of 31 Dec 2023 | 4.66m | 4.44% |
| Hwabao WP Fund Management Co., Ltd.as of 31 Dec 2023 | 4.18m | 3.98% |
| HSBC Jintrust Fund Management Co. Ltd.as of 31 Dec 2023 | 3.47m | 3.31% |
| Golden Eagle Asset Management Co., Ltd.as of 31 Dec 2023 | 2.93m | 2.79% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
